Shionogi Company Limited

Nissin Chemical Industry Co., Ltd.

Nisshin Chemical Co., Ltd.

Shin-etsu Chemical Co., Ltd.

Nisshin Chemical Industry Co., Ltd.

Izumi Saitoh

Shigeru Kido

Shohei Egawa

Yoshio Doi

Kaori Ikeda

Yoshio Sasaki

Yasuyuki Yoshioka

Masayuki Takahira

Toshio Kawakita

Syuichiro Shinohara

Yoshio Sakai

Sakae Obara

Hiroaki Muto

Tohru Chiba

Katsumi Hirose

Hirokuni Jyoyama

Fujio Asanuma

Sumiko Mizuno

Novel crystals of a pyrrolidylthiocarbapenem derivative having excellent stability is provided. According to the present invention, a crystal of (+)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3[[(3S,5S)-5-(sulfamoylaminomethyl)pyrrolidin-3-yl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid having a diffraction pattern in powder X-ray diffraction having main peaks at diffraction angles (2&#x3b8;) of about 6.62, 13.04, 15.44, 16.58, 17.64, 20.88, 23.26, 25.02 and 25.52 (degrees) are provided.

Crystal form of pyrrolidylthiocarbapenem derivative

Novel crystals of a pyrrolidylthiocarbapenem derivative having excellent stability is provided. According to the present invention, a crystal of (+)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3[[(3S,5S)-5-(sulfamoylaminomethyl)p yrrolidin-3-yl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid having a diffraction pattern in powder X-ray diffraction having main peaks at diffraction angles (2&#x3b8;) of about 13.04, 14.98, 15.88, 16.62, 20.62, 21.06, 22.18, 23.90, 26.08, 28.22 and 28.98 (degrees) and a crystal of said compound having a diffraction pattern in powder X-ray diffraction having main peaks at diffraction angles (2&#x3b8;) of about 6.62, 13.04, 15.44, 16.58, 17.64, 20.88, 23.26, 25.02 and 25.52 (degrees) are provided.

A method of applying a skin-protective composition which comprises an acrylic copolymer which comprises

Method of applying a skin-protective composition

A skin-protecting composition which comprises a silicone-acrylic copolymer which comprises

Skin-protecting composition

A novel endermic medicament having a consistency of a gel is proposed which is formulated, as a gel base, with non-ionic water-soluble cellulose ether, e.g., methyl cellulose and hydroxypropyl methyl cellulose, modified with a modification agent containing, in the molecule, an alkyl group having 6 to 26 carbon atoms and a functional group having reactivity with the hydroxyl group in the cellulose ether, e.g., stearyl glycidyl ether, decyl glycidyl ether and cetyl epoxide. The endermic medicament formulated with the modified cellulose ether is stable by virtue of the very little interaction between the active ingredients and the gel base and also can exhibit high percutaneous absorptivity of the active ingredients through the human skin.

Endermic medicament with a gel base

A UV light-absorbing skin-protecting composition which comprises an acrylic copolymer comprising (A) a compound of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or a methyl group, X is a group of the formula: ##STR2## in which R.sup.2 is a hydroxy group, R.sup.3 is a hydrogen atom or hydroxy group, R.sup.4 and R.sup.5 are the same or different and each is a hydrogen atom, a lower alkyl group, a lower alkoxy group, a halogen atom, a nitro group, a carboxyl group, a sulfonic acid group or a sulfonamide group and R.sup.6 is a single bond or a methylene group,

UV light-absorbing skin-protecting composition

A pharmaceutical preparation for the treatment of tinea pedis, containing as basic components about 0.1% to about 2.5% of croconazole hydrochloride and about 1%-15% of an ethyl acrylate-methyl methacrylate copolymer in an aqueous alcohol, and if necessary, about 0.1% to about 2.5% of a thickening agent and/or a plasticizer.

Pharmaceutical preparation for tinea pedis

External preparations consisting essentially of about 0.1% to about 5% of tocopherol acetate and/or about 0.05% to about 0.3% of glycyrrhetinic acid, about 1% to about 15% of a methacrylic acid-ethyl acrylate copolymer, and about 0.2% to about 3% of a thickening agent in an alcoholic solvent, wherein said copolymer is characterized by that the monomer ratio of ethyl acrylate to methacrylic acid is within a range from 75/25 to 95/5, with residual monomer being 50 ppm or less and with practically no surfactants.

External preparation of vitamin-E

Film-formation-type antifungal preparations for external application, consisting essentially of about 0.1% to about 1.5% of tolnaphtate, about 10% to about 20% of a dimethylaminoethyl methacrylate-methacrylic acid ester copolymer and 0.5% to about 10% of a medium chain fatty acid ester in an alcoholic solvent but containing practically no water.

Film-formation-type antifungal preparation

An acrylic copolymer of ethyl acrylate and methacrylic acid wherein the weight ratio of ethyl acrylate to methacrylic acid is in a range between 75:25 and 95:5, containing therein a residual monomer content of 50 ppm or less, but substantially no surfactants, and which is useful as agents for protecting the skin and manufactured from the following essential components:

Acrylic copolymer and skin protective

Topical analgesic anti-inflammatory compositions containing a corticosteroid in addition to the conventional efficacy-proven ingredients are disclosed. They may be embodied in an aerosol, a solution and any other type of composition being convenient for administration. More than the sum of effects of the individual ingredients has been proved. In other words, the effects of the salicylate esters and L-menthol are synergistically enhanced by the addition of the corticosteroid. Particularly, the persistency of the analgesic/anti-inflammatory effects of the conventional ingredients has been proved to be dependent upon the the concentration of the corticosteroid in the composition.

Growing community of inventors

Hyogo, Japan

Izumi Saitoh